blackstone-life-sciences
(2)
Scott Requadt
Scott Requadt is the founding CEO of Prolium Bioscience, a New York-based biotech that emerged from stealth in March 2026 with a $50M Series A from RTW and a Phase 1/2-ready CD20xCD3 bispecific T-cell engager, PRO-203, in-licensed from KeyMed Biosciences and InnoCare Pharma for severe autoimmune disease. A lawyer-turned-investor-turned-operator, Requadt spent a decade at Clarus Ventures (later Blackstone Life Sciences) as Managing Director, ran Talaris Therapeutics as CEO from 2018 through its 2023 wind-down, and now sits on the board of ESSA Pharmaceuticals. He trained at McGill, Toronto Law, and Harvard Business School (Baker Scholar), started his career as an M&A attorney at Davis Polk, and has spent the intervening twenty years turning that unusual pedigree into biotech deals.
Andrew Schiermeier
Andrew Schiermeier is the President and CEO of AvenCell Therapeutics, a clinical-stage biotech in Cambridge, Massachusetts and Dresden, Germany building switchable, universal CAR-T cell therapies for hard-to-treat cancers like acute myeloid leukemia. An engineer-turned-operator with a Harvard PhD in applied mathematics, he spent two decades across startups and global pharma - five years at CRISPR pioneer Intellia Therapeutics rising to COO, and a stint running Merck KGaA's oncology business across 60-plus countries - before taking AvenCell's helm in 2021 and leading its $112 million Series B in 2024.